knowledge -WSS

knowledge

author：fashion 2025-10-02 21:07:32 - browse：99534

green electrocardiogram scan. -- health tech coverage from STAT — Adobe

As Bristol Myers Squibb works to build its treatment for a heart condition that can cause difficulty breathing into a blockbuster drug, it’s propped up an algorithm designed to help find more people who are affected.

The algorithm, which is part of software developed by Viz.ai, earlier this month received clearance from the Food and Drug Administration. The tool, called Viz HCM, looks at 12-lead electrocardiograms collected during routine care and flags suspected cases of hypertrophic cardiomyopathy, or HCM, for further evaluation. As part of a multi-year agreement between the companies, BMS — whose drug, Camzyos, is used to treat HCM — provided funding and scientific input for the development of the algorithm.

“BMS has a vested interest in finding more patients with HCM,” said Matthew Martinez, a cardiologist who leads Viz.ai’s HCM medical advisory board. “Why? Because they’re so philanthropic? No, they want to sell more drugs. They want to help more people by identifying more people.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： AstraZeneca chief proposes a novel edit to the drug pricing bill

WSS

PBMs drew scrutiny in House hearing — and so did pharma

How to fix cancer clinical trials' diversity problem

How to fix cancer clinical trials' diversity problem

Crinetics acromegaly drug succeeds in late

'A game

Covid’s new normal has set in amid another rise in cases

entertainment

knowledge

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

Why the drug industry's warnings on the IRA's impact fall short

Alkermes shareholders re

Transgender sports debate: Physicians say bans are health issue

Dobbs anniversary: the lost opportunity of abortion as health care

AstraZeneca chief proposes a novel edit to the drug pricing bill

Novavax promises a turnaround & Lilly roils the obesity market

Why Novartis is changing the name of its research labs

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Listen: Biogen's potential pivot, & Illumina's next chapter

entertainment

Humana sues Biden admin over Medicare Advantage audit rule

Chamber of Commerce, DOJ clash in court over drug prices

White House Covid adviser calls on docs to combat misinformation

'Make People Better': The CRISPR babies story you probably don't know

Illumina names Agilent executive as new CEO

Covid hospitalizations on the rise, Humana says

Wikipedia

Wikipedia

focus

focus